Olema Oncology (OLMA) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary
Event summary combining transcript, slides, and related documents.
Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary
10 Jun, 2026Strategic focus and pipeline overview
Focused on ER+, HER2- breast cancer, the most common malignancy in women, with two clinical phase assets: palazestrant and a KAT6 inhibitor.
Palazestrant is in two phase III trials (OPERA-01 and OPERA-02), with the first readout expected in fall from OPERA-01.
KAT6 inhibitor showed monotherapy activity in ER+, HER2- breast cancer and castration-resistant prostate cancer; combinations with fulvestrant and palazestrant are ongoing.
Cash position at end of Q1 was $505 million, providing runway into the second half of 2028, covering ongoing trials and potential commercialization.
Clinical trial updates and timelines
OPERA-01 top-line data expected in fall, with results for both mutant and wild-type populations to be announced.
OPERA-02 is enrolling well, with design differences from other trials to better mimic current practice patterns.
KAT6 combination data with fulvestrant may be available by year-end or early next year.
Expansion into castration-resistant prostate cancer and potential consideration for other indications like ovarian and lung cancer based on preclinical signals.
KAT6 inhibitor program insights
Monotherapy data showed antitumor activity and favorable tolerability, with lower rates of Grade 3 neutropenia compared to Pfizer's program.
Collaboration with Bayer to combine KAT6 inhibitor with NUBEQA in prostate cancer.
Ongoing evaluation of triplet combinations (KAT6, palazestrant, CDK4/6) depending on tolerability and efficacy data.
Latest events from Olema Oncology
- Q1 OPERA-01 data will shape a potential mid-2028 launch and broader treatment opportunity.OLMA
Stifel 2026 Healthcare Conference 2026 - OPERA-01 data in Q1 2027 will test palazestrant across both ESR1 subsets.OLMA
3rd Annual Guggenheim Healthcare Innovation Conference - Clinical spending deepened losses, while cash runway is projected through mid-2028.OLMA
Q3 2026 - Phase III breast cancer trial readout for palazestrant expected Q1 2027; new combo data due next year.OLMA
H.C. Wainwright 28th Annual Global Investment Conference - Palazestrant and KAT6 programs offer strong differentiation and major market potential, with key data ahead.OLMA
Morgan Stanley 24th Annual Global Healthcare Conference - Phase III breast cancer trials for palazestrant target major markets, with key data due in Q1 2027.OLMA
Citigroup’s Biopharma Back to School Summit 2026 - Net loss rose 44% to $63.2M in Q2 2026 as Phase 3 trial enrollment completed and cash reached $461M.OLMA
Q2 2026 - Pivotal trials and new combinations position the pipeline for major advances in breast cancer care.OLMA
Jefferies London Healthcare Conference 2025 - Promising clinical progress and strategic trial updates position the pipeline for significant impact.OLMA
Jefferies Global Healthcare Conference 2026